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Objective: Although smoking cessation is recommended for all patients with peripheral artery disease, there are little data
regarding the prevalence of smoking among patients at the time of angiography or the effect of smoking cessation on
clinical outcomes.
Methods: Consecutive patients with claudication or critical limb ischemia who underwent peripheral angiography from
2006 to 2013 were included in an observational cohort analysis. Smoking status was assessed at the time of angiography
and during follow-up clinic visits. Kaplan-Meier analysis was used to assess the relationship between smoking cessation,
mortality, and amputation-free survival.
Results: Among 739 patients (423 men and 316 women; mean age, 60 6 12 years), 204 (28%) remained active smokers at
the time of lower extremity angiography. At the time of angiography, the mean number of cigarettes smoked per day was
16 6 10, and the mean pack-years was 40 6 25. During the course of the subsequent year, 61 patients (30%) successfully
quit smoking and maintained continued abstinence. Baseline medication use between groups did not differ signiﬁcantly.
The mean ankle-brachial index was also similar for quitters vs nonquitters (0.53 6 24 vs 0.49 6 0.22; P [ .3). During
follow-up to 5 years, patients who quit smoking had signiﬁcantly lower all-cause mortality (14% vs 31%; hazard ratio,
0.40; 95% conﬁdence interval, 0.18-0.90) and improved amputation-free survival (81% vs 60%; hazard ratio, 0.43, 95%
conﬁdence interval, 0.22-0.86) compared with patients who continued smoking, with most of the difference driven by
reduced mortality among patients who quit smoking. The ﬁndings remained signiﬁcant on multivariable analysis.
Conclusions: Approximately one-third of active smokers with peripheral artery disease successfully quit smoking #1 year
after lower extremity angiography. Patients who quit smoking have lower mortality and improved amputation-free
survival compared with patients who continue smoking. (J Vasc Surg 2014;60:1565-71.)Smoking is a major contributor to the development
of peripheral artery disease (PAD) and a risk factor for a
number of other cardiovascular complications, including
coronary artery disease, stroke, and myocardial infarc-
tion.1-4 Among patients with established PAD, continued
smoking is also associated with lower rates of lower extrem-
ity bypass graft patency and increased risk of amputation.5,6
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patients with PAD.7-9
Despite the known risks of smoking and counseling for
smoking cessation, a signiﬁcant percentage of patients with
PAD continue to smoke.10,11 A number of therapies have
been developed to assist with smoking cessation, including
nicotine replacement, centrally acting antidepressants (eg,
bupropion), and partial agonists of the nicotine receptor
(eg, varenicline).12-14 Even with these medications, most
patients with PAD who smoke have low rates of successful
cessation during follow-up.
Although smoking cessation is recommended for all
patients with PAD, only a few observational studies have
examined the relationship between smoking cessation and
subsequent cardiovascular and limb-related outcomes.15-19
These studies suggest that smoking cessation is associated
with improved limb-related and cardiovascular outcomes,
but the patients studied were from a general population
of patients with PAD rather than patients with more
advanced lower extremity ischemia. Most of these studies
were also conducted before modern smoking cessation
therapies were developed. In this study, we assessed the
relationship between successful smoking cessation
#1 year after lower extremity angiography and subse-
quent cardiovascular and limb-related outcomes.1565
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The University of California, Davis Medical Center
Institutional Review Board approved the protocol for this
study, with waiver of informed consent.
Study design and data collection. This was a retro-
spective study using the PAD-University of California,
Davis Registry. This registry includes all patients with PAD
and obstructive disease leading to claudication or critical
limb ischemia (CLI) who underwent diagnostic lower ex-
tremity angiography or endovascular intervention, or both,
at the University of California, Davis Medical Center be-
tween June 1, 2006, and May 1, 2013.20 Patients with
aneurysmal disease or acute limb ischemia were excluded.
All patients in the registry with claudication or CLI were
analyzed for this analysis.
Data collection was based on electronic medical record
and angiographic review. Demographic, clinical, labora-
tory, and procedural data were obtained through preproce-
dure clinical notes, admission history, and in-patient
documentation. Also recorded were medical comorbidities,
including history of myocardial infarction, stroke, coronary
artery disease, and chronic kidney disease. Medications at
the time of the procedure were assessed. All records were
reviewed by trained chart abstractors and veriﬁed by a
board-certiﬁed cardiologist.
Smoking was assessed by patient self-report in clinic
notes. Patients were seen before the procedure in the
vascular clinic, where smoking use is routinely quantiﬁed.
At our institution, any patient seen at the vascular center
who is an active smoker is seen by a nurse practitioner dedi-
cated to educating and counseling patients on smoking
cessation, with referral to a comprehensive smoking cessa-
tion program within our institution. The number of ciga-
rettes smoked per day at the time of angiography was
assessed by patient self-report of smoking intensity. Pack-
years were derived from patient report of age at which
the patient started smoking and the average number of
packs smoked per day during that period, which is
routinely captured in the electronic medical record.
Abstention from smoking during follow-up was
assessed by patient self-report of cessation, which was
routinely asked at all follow-up clinic visits. A patient who
reported continued abstention from smoking #1 year after
the lower extremity angiogram was categorized as a suc-
cessful quitter. Aids to smoking cessation, including use
of nicotine replacement and other pharmacologic aids,
were assessed by patient report and pharmacy records of
drug prescriptions.
The primary study outcome was all-cause mortality. All
deaths were conﬁrmed by direct record documentation or
the Social Security Death Index.
Myocardial infarction was deﬁned as symptoms of chest
pressure and elevation of troponin with evidence of infarct
by stress imaging or cardiac catheterization. Stroke was
deﬁned as focal neurologic deﬁcit with computed tomogra-
phy or magnetic resonance imaging evidence of cerebral
ischemic or hemorrhagic infarct. Major adverse limb events(MALEs) were deﬁned as major lower extremity limb
amputation above the level of the ankle joint, thrombolysis,
or surgical bypass.21 Claudication was classiﬁed as Ruther-
ford category 1 to 3 disease (mild, moderate, or severe
claudication, respectively), and CLI was classiﬁed as Ruth-
erford category 4 to 6 disease (ischemic rest pain, minor tis-
sue loss, or major tissue loss, respectively).22
Data analysis. Means with standard deviations are
used to describe continuous variables, and frequencies
and percentages are used for categoric variables. Contin-
uous variables were compared using the Wilcoxon rank
sum test and categoric values using c2 or Fisher exact tests.
Survival curves for patients who successfully quit smoking
vs those who continued smoking were estimated using
the Kaplan-Meier method. A Cox proportional hazard
model was also developed to assess the relationship be-
tween smoking cessation and subsequent outcomes. The
ﬁnal model included adjustment for age, diabetes, coronary
artery disease, prior myocardial infarction, glomerular
ﬁltration rate, prescriptionof statinmedications, prescription
of angiotensin-converting enzyme inhibitors, prescription of
b-blockermedications, and baseline ankle-brachial index. All
analyses were performed using Stata 13.2 software (Stata
Corp LP, College Station, Tex). Hazard ratios (HRs) are
provided with 95% conﬁdence intervals (CIs). For all tests, a
P value of <.05 was considered signiﬁcant.
RESULTS
Among 739 patients with claudication or CLI referred
for lower extremity angiography between 2006 and 2012,
204 (28%) were active smokers. During the course of the
subsequent year, 61 patients (30%) successfully quit smok-
ing and maintained continued abstinence (Table I).
Compared with nonquitters, quitters were of similar age,
sex, and ethnicity, but successful quitters were less likely
to have a history of coronary artery disease (26% vs 46%;
P ¼ .007). Prescription of cardiovascular medications,
including aspirin, statin medications, and angiotensin-
converting enzyme inhibitors, was similar between groups.
The baseline Rutherford classiﬁcation was not signiﬁcantly
different between groups. The mean ankle-brachial index
was also similar for quitters vs nonquitters (0.53 6 24 vs
0.49 6 0.22; P ¼ .3). Diagnostic lower extremity angiog-
raphy and subsequent surgical bypass were performed in
23% of patients, and the remainder underwent endovascular
intervention. The overall procedural success of patients
undergoing endovascular intervention was 93% and did
not differ between quitters vs nonquitters (89% vs 95%;
P ¼ .2). At 30 days after the procedure, the mean improve-
ment in Rutherford classiﬁcation was similar between quit-
ters vs non-quitters (1.6 vs 1.7; P ¼ .8). There were also no
differences in quit rates between patients initially presenting
with claudication vs CLI (29% vs 30%; P ¼ .9).
Among patients who were active smokers at the time of
angiography, a mean of 16 6 10 cigarettes were smoked
per day, and the mean pack-years was 40 6 25. Those
who successfully quit smoked a similar number of cigarettes
Table II. Smoking habits among quitters vs nonquitters
Variablea Quit smoking (n ¼ 61) Continued smoking (n ¼ 143) P value
Cigarettes smoked per day 15 6 12 16 6 10 .7
Pack-years 44 6 37 36 6 22 .04
Attempted quitting 61 (100) 34 (25) <.001
Type of cessation aid .8
Nicotine replacement 4 (7) 15 (10)
Varenicline 3 (5) 10 (7)
Bupropion 1 (2) 4 (3)
None 53 (87) 114 (80)
aContinuous data are reported as mean 6 standard deviation and categoric data as number (%).
Table I. Baseline demographicsa
Variableb Quit smoking (n ¼ 61) Continued smoking (n ¼ 143) P value
Age, years 62 6 10 60 6 12 .3
Male 32 (52) 86 (60) .3
Race/ethnicity .7
Caucasian 54 (89) 129 (90)
Hispanic 3 (5) 3 (2)
African American 4 (6) 10 (7)
Asian 0 1 (1)
Body mass index, kg/m2 28 6 5 27 6 6 .2
Congestive heart failure 5 (8) 20 (14) .2
Diabetes mellitus 23 (38) 57 (42) .6
GFR, mL/min 85 6 41 88 6 48 .7
Hypertension 52 (85) 110 (78) .2
Coronary artery disease 16 (26) 66 (46) .007
COPD 13 (21) 40 (29) .3
History of
Myocardial infarction 11 (18) 25 (17) .9
Stroke/TIA 6 (10) 25 (17) .2
Malignancy 5 (8) 14 (10) .7
AAA 4 (7) 4 (3) .2
Carotid stenosis 5 (9) 21 (16) .1
Contralateral amputation 2 (3) 16 (11) .2
Medication use
Statin 33 (54) 83 (58) .6
Aspirin 54 (88) 123 (86) .7
b-blocker 24 (39) 71 (50) .2
ACE inhibitor 34 (55) 72 (50) .5
Rutherford score .8
1 3 (5) 6 (4)
2 10 (16) 31 (22)
3 13 (21) 26 (18)
4 5 (8) 19 (13)
5 25 (41) 47 (33)
6 5 (8) 12 (8)
Ankle-brachial indexc 0.49 6 0.22 0.54 6 0.23 .3
Type of procedure performed .1
Diagnostic only 18 (30) 29 (20)
Femoropopliteal 20 (33) 37 (26)
Infrapopliteal 23 (38) 76 (53)
Procedural success 42 (89) 110 (95) .2
AAA, Abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; GFR, glomerular ﬁltration rate;
TIA, transient ischemic attack.
aProcedural success is reported among the subgroup of patients who underwent endovascular intervention.
bContinuous data are reported as mean 6 standard deviation and categoric data as number (%).
cNoncompressible values were excluded.
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daily; P ¼ .7), but had signiﬁcantly greater average pack-
year smoking history (44 6 37 vs 36 6 22 pack years;
P ¼ .04) than nonquitters. Only a minority of patientsused smoking cessation aids such as nicotine replacement
or other pharmacologic agents (Table II). Among patients
who failed to quit smoking, 25% attempted to quit in the
subsequent year but ultimately resumed smoking.
Fig 1. Kaplan-Meier curves show (A) mortality, (B) rates of major amputation, and (C) amputation-free survival
among patients who continued (solid line) vs quit (dashed line) smoking.
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at the time of lower extremity angiography had lower rates
of 5-year mortality (HR, 0.66; 95% CI, 0.47-0.93) but
similar rates of major amputation (HR, 0.85; 95% CI,
0.50-1.45) and amputation-free survival (HR, 0.76; 95%
CI, 0.57-1.03) compared with patients who were active
smokers at the time of angiography. This difference in out-
comes based on initial smoking status was explained by
improved outcomes among patients who subsequently
quit smoking vs continued poor outcomes among patients
who continued smoking.
During follow-up to 5 years after the procedure,
patients who quit smoking #1 year after lower extrem-
ity angiography had signiﬁcantly lower unadjusted rates
of all-cause mortality (absolute event rate of 14% vs
31%; HR, 0.40; 95% CI, 0.18-0.90) and improved
amputation-free survival (absolute event-free rate of
81% vs 60%; HR, 0.43; 95% CI, 0.22-0.86) compared
with patients who continued smoking (Fig 1). Event
rates of myocardial infarction, stroke, major amputation,
and MALEs also all favored smoking cessation, although
these individual end points were not statistically signiﬁ-
cant. Similar results were observed when the analysis
was limited to the 414 patients who initially presented
with CLI, of whom 107 were active smokers at the
time of angiography. A signiﬁcantly reduced risk of mor-
tality and improved amputation-free survival was noted
among patients with CLI who quit smoking (Fig 2),although most of the difference in amputation-free sur-
vival was driven by lower mortality among the patients
who successfully quit smoking.
Univariate analysis revealed several other predictors of
mortality and major amputation among active smokers at
the time of lower extremity angiography, including age,
diabetes, coronary artery disease, prior myocardial infarc-
tion, and ankle-brachial index (Table III). On multivariable
analysis after adjusting for age, medical comorbidities, and
other medical treatment, smoking cessation remained asso-
ciated with a signiﬁcantly reduced mortality (adjusted HR,
0.33; 95% CI, 0.13-0.80), improved amputation-free sur-
vival (adjusted HR, 0.40; 95% CI, 0.19-0.83), and a
nonsigniﬁcant trend toward beneﬁt for other secondary
outcomes (Table IV). Similar point estimates were ob-
tained on multivariable analysis among patients with CLI.
DISCUSSION
In this study, we assessed the relationship between suc-
cessful smoking cessation during the year after lower ex-
tremity angiography among patients with lifestyle-limiting
claudication or CLI. Our major ﬁndings were that one-
third of long-term smokers successfully quit in the year af-
ter angiography and that successful smoking cessation was
associated with signiﬁcantly decreased mortality and
improved amputation-free survival during 5 years of
follow-up. These ﬁndings remained signiﬁcant after multi-
variable adjustment, suggesting that successful smoking
Fig 2. Kaplan-Meier curves show (A) mortality, (B) rates of major amputation, and (C) amputation-free survival
among patients with critical limb ischemia (CLI) who continued (solid line) vs quit (dashed line) smoking.
Table III. Univariate associations for mortality and major amputation among active smokers at the time of lower
extremity angiography
Variable
Mortality Major amputation
HR (95% CI) P value HR (95% CI) P value
Smoking cessation 0.40 (0.18-0.90) .03 0.38 (0.11-1.31) .1
Age 1.04 (1.03-1.05) .001 0.99 (0.97-1.01) .3
Male gender 1.16 (0.88-1.53) .3 0.73 (0.45-1.18) .2
Diabetes 1.38 (1.04-1.83) .03 2.64 (1.57-4.44) .001
Coronary artery disease 1.54 (1.16-2.04) .003 1.06 (0.66-1.69) .8
Myocardial infarction 1.70 (1.23-2.34) .001 1.71 (1.02-2.87) .04
Statin medications 0.77 (0.57-1.02) .07 0.54 (0.34-0.85) .009
ACE inhibitors 0.80 (0.60-1.06) .1 0.64 (0.40-1.02) .06
b-blocker medications 1.71 (1.30-2.32) .001 1.56 (0.97-2.52) .07
GFR 0.98 (0.97-0.98) .001 0.99 (0.98-0.99) .02
Ankle-brachial index 0.11 (0.04-0.31) .001 0.10 (0.02-0.51) .006
ACE, Angiotensin-converting enzyme; CI, conﬁdence interval; GFR, glomerular ﬁltration rate; HR, hazard ratio.
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tality among patients with claudication or CLI.
At the time of the initial lower extremity angiography,
28% of patients in the overall cohort were active smokers.
All of the patients in this study were followed up in a multi-
disciplinary vascular clinic where smoking cessation coun-
seling is routinely provided. The decision to pursue lower
extremity angiography and possible endovascular interven-
tion among active smokers with claudication is controver-
sial, because continued smoking is associated with
progression of PAD and decreased graft patency. Amongpatients with CLI, the presence of a threatened limb may
necessitate angiography and intervention, regardless of
smoking status.
We found no difference in the baseline presentation or
severity of disease among patients who quit vs continued
smoking, suggesting that successful quitting was not driven
by patient symptoms of continued lower extremity
ischemia. In fact, the only signiﬁcant demographic differ-
ence between quitters vs nonquitters was a lower preva-
lence of coronary artery disease among patients who
successfully quit. These ﬁndings and prior studies suggest
Table IV. Unadjusted and adjusted 5-year outcomes among patients who quit smoking
Outcome
Event rate, % (95% CI)
Unadjusted HR (95% CI) Adjusted HR (95% CI)aQuitters Nonquitters
Mortality 14 (7-27) 31 (23-40) 0.40 (0.18-0.90) 0.33 (0.13-0.80)
Amputation-free survival 81 (10-32) 60 (31-50) 0.43 (0.22-0.86) 0.40 (0.19-0.83)
Myocardial infarction 8 (3-20) 16 (8-31) 0.72 (0.22-2.31) 0.68 (0.20-2.30)
Stroke 2 (1-14) 5 (2-15) 0.44 (0.10-3.98) 0.58 (0.10-5.60)
Major amputation 7 (2-15) 22 (12-37) 0.38 (0.11-1.31) 0.43 (0.12-1.57)
MALE 33 (21-49) 31 (19-45) 1.40 (0.80-2.70) 1.40 (0.69-2.82)
CI, Conﬁdence interval; HR, hazard ratio; MALE, major adverse limb event.
aIncludes adjustment for age, diabetes, coronary artery disease, prior myocardial infarction, glomerular ﬁltration rate, prescription of statin medications,
prescription of angiotensin-converting enzyme inhibitors, and prescription of b-blocker medications.
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rather than overall health status, may play a larger role in
successful smoking cessation.23
During the course of 1 year after lower extremity
angiography, approximately one-third of active smokers
successfully quit smoking and maintained abstinence
from smoking. Prior studies of smoking cessation in the
general population have reported low overall rates of suc-
cessful abstinence, ranging from 5% with counseling to
30% with more recent pharmacologic approaches.13,14
Most of these studies have reported 6-month rates of
abstention, which may be higher than 1-year rates of
smoking abstinence. In the only randomized trial of inten-
sive smoking cessation counseling among patients with
PAD, intensive counseling resulted in a successful absti-
nence rate of 21% vs 6.8% in the control group.11 Only
a minority of patients in our cohort used counseling or
adjunctive pharmacologic aids. The reasons for this are
uncertain, but prior studies have suggested that many pa-
tients are hesitant to use pharmacologic therapies to assist
with smoking cessation.24 These ﬁndings suggest that the
time of ﬁrst angiography among patients with PAD is an
opportunity to further reinforce the beneﬁts of smoking
cessation. It is possible that a more structured intervention
at the time of lower extremity angiography and the
months afterward could possibly successfully increase rates
of quitting to a higher level than we observed in this
observational study.
Most of the beneﬁt from smoking cessation was re-
ﬂected by reduced overall mortality, with an absolute mor-
tality of 14% at 5 years among successful quitters vs 31%
among patients who continued smoking. This mortality
beneﬁt was even more apparent among the subgroup of pa-
tients with CLI, where the absolute 5-year mortality rates
were 18% vs 43% (P ¼ .03). To our knowledge, this study
is the ﬁrst systematic investigation of the beneﬁts of smok-
ing cessation among patients with CLI. Given the high
mortality of patients with CLI, smoking cessation may
have particular beneﬁt in these patients, especially because
the beneﬁts of smoking cessation extended to amputation-
free survival. Although there was no difference in MALEs
among patients who quit vs continued smoking, this was
likely due to the higher rates of lower extremity bypassperformed among patients who successfully quit smoking.
Given the known association between smoking and early
graft failure, the differential rates of surgical bypass are
likely related to physician decision making.25 A larger study
would likely be necessary to detect signiﬁcant differences in
rates of major amputation among patients who quit vs
continued smoking.
This study has several limitations: First, this was an
observational cohort study. Other unmeasured con-
founders might possibly account for the apparent differ-
ences in outcomes among patients who quit smoking vs
those who continued smoking.
Second, we relied on patient self-report of smoking
cessation. It is possible that patients under-reported their
cigarette intake or did not actually quit smoking. However,
the presence of continued smokers in the cohort of patients
considered to have quit would bias the results towards the
null, thereby suggesting that our ﬁndings remain valid.
Third, the small size of the overall cohort likely resulted
in nonsigniﬁcant ﬁndings regarding the effects of smoking
cessation on myocardial infarction, stroke, and other sec-
ondary outcomes. Smoking cessation would likely be asso-
ciated with a beneﬁt for each of these end points if studied
in a larger cohort.
CONCLUSIONS
One-third of active smokers with claudication or CLI
successfully quit smoking in the year after lower extremity
angiography. Successful smoking cessation was associated
with decreased mortality and improved amputation-free
survival during follow-up to 5 years. These ﬁndings should
provide additional impetus to encourage smoking cessation
among all patients with PAD.
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